SNOWMASS VILLAGE, COLO.—Data from three recent trials in systemic sclerosis (scleroderma) provide information on a number of important issues related to screening and treatment. First presented at the 2018 ACR/ARHP Annual Meeting, the phase 2/3 trials assessed the safety and efficacy of targeted agents to treat patients with systemic sclerosis.1-3 In a follow-up presentation at…
In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…
NEW YORK (Reuters Health)—Early immune response signatures in the critically injured may shed light on mechanisms underlying multiple organ system failure, according to U.K. investigators. As Dr. Joanna M. Shepherd of Queen Mary University of London tells Reuters Health by email, “Multiple organ dysfunction syndrome (MODS) is common after major trauma and it contributes to…